AutoImmune is a biopharmaceutical company involved in the development of treatments for autoimmune and cell-mediated inflammatory diseases and conditions.
This release contains forward-looking statements that involve risks and
uncertainties. The Company's actual results may differ significantly from
results discussed in the forward-looking statements due to a number of
important factors, including, but not limited to the uncertainties of
clinical trial results, the Company's dependence on third parties for
licensing revenue, and the risks of technological change and competition.
These factors are more fully discussed in the Company's most recent Annual
Report on Form 10-KSB filed with the Securities and Exchange Commission in
the section "Risk Factors." The discussion in the Annual Report on Form
10-KSB is hereby referenced into this release.
- Financial Chart Follows -
STATEMENT OF OPERATIONS
Three months ended Year ended
December 31, December 31,
2006 2007 2006 2007
Revenue $137,000 $75,000 $401,000 $294,000
Costs and expenses:
Cost of product revenue 28,000 1,000 46,000 21,000
Research and development 45,000 49,000 217,000 144,000
Selling, general and
administrative 152,000 181,000 1,058,000 713,000
Total costs and
expenses 225,000 231,000 1,321,000 878,000
Interest income 113,000 105,000 428,000 440,000
Minority interest in
joint venture 11,000 (5,000)
|SOURCE AutoImmune Inc.|
Copyright©2008 PR Newswire.
All rights reserved